Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) granted inducement stock options totaling 10,700 shares to newly hired employees on April 22, 2026 under its 2024 Inducement Plan in reliance on Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price equal to the closing price on the grant date and vest over four years: 25% at the first anniversary, then monthly thereafter, subject to continued employment.

News Market Reaction – ALGS

+4.40%

6 alerts

+4.40% Session close to close

+2.3% Peak in 2 hr 30 min

$40.62M Market Cap

0.2x Rel. Volume

In the Apr 24 session, ALGS gained 4.40%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.3% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details inducement stock option grants covering 10,700 shares under Aligos’ 2024 I...

Analysis

This announcement details inducement stock option grants covering 10,700 shares under Aligos’ 2024 Inducement Plan, with a 4-year vesting schedule and 25% cliff after one year. It follows months of significant licensing, clinical, and financial disclosures, including narrowed 2025 losses and defined cash runway. Investors monitoring the story may focus more on upcoming clinical milestones, funding developments, and further regulatory filings than on this routine compensation-related item.

Key Figures

Inducement options: 10,700 shares Grant date: April 22, 2026 Initial vesting: 25% +1 more

4 metrics

Inducement options 10,700 shares Non-qualified stock options granted under 2024 Inducement Plan

Grant date April 22, 2026 Inducement stock option grant date

Initial vesting 25% Portion vesting on first anniversary of grant date

Vesting period 4 years Total vesting term for inducement stock options

Historical Context

5 past events · Latest: Apr 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 16	License deal	Positive	+3.2%	Exclusive Greater China license for pevifoscorvir with upfront and milestones.
Apr 14	Clinical update	Positive	-15.1%	Phase 2 interim B-SUPREME data and FDA Fast Track for HBV candidate.
Mar 05	Earnings report	Positive	-2.9%	Q4 and 2025 results with narrowed net loss and defined cash runway.
Feb 26	Earnings date notice	Neutral	+8.1%	Announcement of scheduled Q4 2025 earnings release date and timing.
Feb 23	Clinical data	Positive	+2.1%	Positive CROI data on pevifoscorvir and ALG-097558 pharmacokinetics.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed reactions: some positive clinical and deal news aligned with gains, but several favorable updates (including trial and earnings-related items) coincided with selloffs, suggesting a tendency for good news to be met with skepticism.

Recent Company History

Over the last few months, ALGS reported multiple milestones, including a regional licensing deal with Amoytop promising up to $445M in economics, interim Phase 2 B-SUPREME data with FDA Fast Track status, and 2025 results showing net loss narrowed to $24.2M with cash of $77.8M. Price reactions were inconsistent: some positive trial and conference data saw modest gains, while interim Phase 2 data and earnings updates triggered declines, framing today’s routine inducement grants against a backdrop of volatile responses to fundamental news.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, exercise price, vesting

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"grants under Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 10,700 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"have an exercise price per share equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to the Inducement Grant will vest over a four-year period"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 10,700 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on April 22, 2026 (the “Grant Date”), in connection with the commencement of employment.

The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.

The Inducement Grants have an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with 25% vesting on the first anniversary of the Grant Date and the remainder vesting in equal monthly installments, subject to the continued employment through the applicable vesting dates.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2026 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Aligos Therapeutics

Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

FAQ

What did Aligos Therapeutics (ALGS) announce about inducement grants on April 24, 2026?

Aligos granted non-qualified stock options for an aggregate of 10,700 shares to newly hired employees. According to the company, the awards were made under its 2024 Inducement Plan and rely on Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and grant date for ALGS inducement options?

The exercise price equals the closing price of Aligos common stock on the grant date, April 22, 2026. According to the company, the options were priced at that closing market price on the Grant Date.

How do the Aligos (ALGS) inducement stock options vest?

The inducement options vest over four years with 25% vesting at the first anniversary and the remainder vesting in equal monthly installments. According to the company, vesting is subject to continued employment through each vesting date.

Why did Aligos (ALGS) use an inducement plan for these grants?

Aligos used its 2024 Inducement Plan to grant awards exclusively to individuals not previously employed by the company. According to the company, the grants served as an inducement material to those individuals commencing employment.

Does the Aligos (ALGS) announcement state any immediate financial guidance or dilution impact?

No immediate financial guidance or quantified dilution impact was provided in the announcement. According to the company, the notice describes grant terms, exercise price, and vesting but does not state share-count impact or guidance changes.